Novel mTORC1 Inhibitors Kill Glioblastoma Stem Cells
Glioblastoma (GBM) is an aggressive tumor of the brain, with an average post-diagnosis survival of 15 months. GBM stem cells (GBMSC) resist the standard-of-care therapy, temozolomide, and are considered a major contributor to tumor resistance. Mammalian target of rapamycin Complex 1 (mTORC1) regulat...
Na minha lista:
| Principais autores: | , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI AG
2020-11-01
|
| coleção: | Pharmaceuticals |
| Assuntos: | |
| Acesso em linha: | https://www.mdpi.com/1424-8247/13/12/419 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|